CJC-1295 + Ipamorelin
A pre-mixed blend of CJC-1295 (no DAC) and Ipamorelin. No controlled study has tested the blend itself; this hub covers the math and what each part has been studied for.
Key facts
- Class
- GHRH + GHRP blend
- Pre-mixed blend
- Also called
- CJC/Ipa
- Vial sizes sold
- 10 mg
- Community-reported sizes
- Half-life
- 2 hours terminal half-life
- intravenous infusion (15 min), in people · Pharmaceutical research 1999, PMID 10496658
- FDA status
- Not approved
- research blend
- WADA
- Prohibited (S2.2.4)
- In and out of competition
CJC-1295 + Ipamorelin guides
Questions
What is in it
Amounts per vial vary by seller. No controlled study has tested the blend itself.
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies. CJC-1295 + Ipamorelin itself has not been studied; grades come from its ingredients' studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Muscle growth | 1 | 0 | 6 | Human observational evidence, 3 of 4CJC-1295: Substance use & misuse 2016, PMID 26771670 |
| Weight loss | Not in our ledger | Not in our ledger | 2 | Human observational evidence, 3 of 4CJC-1295: Substance use & misuse 2016, PMID 26771670 |
| Hormone balance | Not in our ledger | Not in our ledger | 2 | Human RCT evidence, 4 of 4CJC-1295: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Men | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence files for CJC-1295 and Ipamorelin, each quote checked against the abstract or label.
Two different mechanisms in one vial
CJC-1295 is a long-acting GHRH analogue: in healthy adults a single injection raised mean plasma GH 2- to 10-fold for 6 days or more.[6]
Ipamorelin acts on a different receptor: it was described as the first GHRP-receptor agonist with a selectivity for GH release similar to GHRH.[13]
Ipamorelin's volunteer study showed a single episode of GH release peaking at 0.67 hours, a very different time course from the multi-day CJC-1295 response.[5]
Tested together?
The cached PubMed search for both names returned 10 records, and none was classed as testing the two together.[14]
A recent review of growth-hormone-axis peptides notes the absence of approval for physique or performance uses and uncertainty about product composition, dose and stacking in unregulated supply chains.[15]
Sport and regulation
WADA's list names CJC-1295 among GHRH analogues.[1]
Ipamorelin appears on the same list among growth hormone secretagogues and their mimetics.[1]
Compared with
Common stacks
CJC-1295 + Ipamorelin is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is CJC-1295 + Ipamorelin FDA approved?
No. CJC-1295 + Ipamorelin is not FDA approved for any use.
What is in CJC-1295 + Ipamorelin?
CJC-1295 (no DAC) and Ipamorelin, pre-mixed in one vial. Amounts per vial vary by seller and are rarely verified.
Is CJC-1295 + Ipamorelin banned in sport?
Yes. Prohibited by WADA (S2.2.4), so it is prohibited at all times for tested athletes.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is CJC-1295 with ipamorelin?
A blend of a GHRH analogue and a GHRP-receptor agonist, each of which raises growth hormone by a different route.[6]
Has CJC-1295 plus ipamorelin been studied?
Not as a pair: the search returned 10 records mentioning both and none tested them together.[14]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: Not an approved product anywhere; see components (CJC-1295 (no DAC), Ipamorelin). Drugs@FDA (openFDA) search for the component CJC-1295 (no DAC) returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
- 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 5Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 7PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 10PubMed search (Ipamorelin): ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search (Ipamorelin): ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search (Ipamorelin): ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 14Official web pageOfficial web page · web page
- 15The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
Found an error? Report a correction.